Glucose levels change rapidly after meals, exercise, or the injection of insulin. For diabetics, self-monitoring of blood glucose is vitally important for managing fluctuations and knowing when to administer their medication and how much. Measurements are taken several times a day and generally require blood from a finger prick. Although the procedure is simple, patients dislike the frequency of sampling and accompanying discomfort. AstraZeneca seeks a minimally invasive approach to measure blood glucose without the need for blood sampling.
This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing an AstraZeneca funded collaborative partnership.
The most frequently used method to monitor glucose levels requires a sample of blood to be applied to a glucose test strip. This provides an accurate measurement of blood glucose via a handheld device. Diabetic and hypoglycemic patients often need to check their glucose levels multiple times a day. This regular sampling causes pain and discomfort and leads to non-compliance and potential mismanagement of glucose levels. AstraZeneca seeks a minimally invasive approach to measure blood glucose without the need for blood sampling.
ABOUT THE SEEKER
AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical research.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on January 10, 2015. Late submissions will not be considered.
This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (including supporting non-confidential information and contact details) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, AstraZeneca may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed upon time frame.
[NOTE: Only proposals from Solvers who have the ability to work as the collaboration partner will be considered.]
What is an eRFP Challenge?
eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.
After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.
This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.